Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | ESRRA | P11474 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966370 | 0.93 | HDAC4 (0.39) | IGF1RPIM1PIM2ESRRAGPR119 | |
| SCHEMBL3965270 | 0.90 | HDAC4 (0.37) | PIM1PIM2ESRRAGPR119HDAC4 | |
| SCHEMBL3968162 | 0.88 | ESRRA (0.38) | IGF1RESRRAHDAC4HPGD | |
| SCHEMBL6246294 | 0.87 | PPARG (0.32) | IGF1RESRRAGPR119HDAC4HPGD | |
| SCHEMBL3971286 | 0.87 | HPGD (0.42) | PIM1PIM2HPGDGPR35AKR1B1 | |
| Hydrochloric Acid SCHEMBL3966186 | 0.86 | HPGD (0.41) | PIM1PIM2HPGDGPR35AKR1B1 | |
| SCHEMBL6246069 | 0.86 | PPARG (0.32) | IGF1RESRRAGPR119HDAC4HPGD | |
| SCHEMBL3974489 | 0.85 | HPGD (0.36) | PIM1PIM2GPR119HDAC4HPGD | |
| SCHEMBL6246085 | 0.84 | HPGD (0.40) | PIM1PIM2HDAC4HPGDGPR35 | |
| SCHEMBL3967375 | 0.83 | PPARG (0.36) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087576-B2 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | claimed |
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
| US-7087576-B2 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005034981-A1 | DIPEPTIDE PHENYL ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | DPP4, GPR119, IAPP | IGF1R 164/4885PIM1 2192/4885PIM2 2727/4885 |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | IGF1R 84/4885PIM1 1418/4885PIM2 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.